Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression

被引:306
作者
Song, KM
Chen, YG
Göke, R
Wilmen, A
Seidel, C
Göke, A
Hilliard, B
Chen, YH
机构
[1] Univ Penn, Sch Med, Inst Human Gene Therapy, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Mol & Cellular Engn, Philadelphia, PA 19104 USA
关键词
autoimmunity; inflammation; apoptosis; cytokine; TRAIL;
D O I
10.1084/jem.191.7.1095
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis of tumor cells but not normal cells; its role in normal nontransformed tissues is unknown. We report here that chronic blockade of TRAIL in mice exacerbated autoimmune arthritis, and that intraarticular TRAIL gene transfer ameliorated the disease. In vivo, TRAIL blockade led to profound hyperproliferation of synovial cells and arthritogenic lymphocytes and heightened the production of cytokines and autoantibodies. In vitro, TRAIL inhibited DNA synthesis and prevented cell cycle progression of lymphocytes. Interestingly, TRAIL had Ilo effect on apoptosis of inflammatory cells either in vivo or in vitro. Thus, unlike other members of the tumor necrosis factor superfamily, TRAIL is a prototype inhibitor protein that inhibits autoimmune inflammation by blocking cell cycle progression.
引用
收藏
页码:1095 / 1103
页数:9
相关论文
共 48 条
[1]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[2]   Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunological analysis [J].
Bettinardi, A ;
Brugnoni, D ;
QuirosRoldan, E ;
Malagoli, A ;
LaGrutta, S ;
Correra, A ;
Notarangelo, LD .
BLOOD, 1997, 89 (03) :902-909
[3]   CELL-AUTONOMOUS FAS (CD95) FAS-LIGAND INTERACTION MEDIATES ACTIVATION-INDUCED APOPTOSIS IN T-CELL HYBRIDOMAS [J].
BRUNNER, T ;
MOGIL, RJ ;
LAFACE, D ;
YOO, NJ ;
MAHBOUBI, A ;
ECHEVERRI, F ;
MARTIN, SJ ;
FORCE, WR ;
LYNCH, DH ;
WARE, CF ;
GREEN, DR .
NATURE, 1995, 373 (6513) :441-444
[4]   Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway [J].
Chaudhary, PM ;
Eby, M ;
Jasmin, A ;
Bookwalter, A ;
Murray, J ;
Hood, L .
IMMUNITY, 1997, 7 (06) :821-830
[5]  
CHEN YH, 1995, J IMMUNOL, V155, P910
[6]   The role of Fas in autoimmune diabetes [J].
Chervonsky, AV ;
Wang, Y ;
Wong, FS ;
Visintin, I ;
Flavell, RA ;
Janeway, CA ;
Matis, LA .
CELL, 1997, 89 (01) :17-24
[7]   THE LPR AND GLD GENES IN SYSTEMIC AUTOIMMUNITY - LIFE AND DEATH IN THE FAS LANE [J].
COHEN, PL ;
EISENBERG, RA .
IMMUNOLOGY TODAY, 1992, 13 (11) :427-428
[8]   The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain [J].
Degli-Esposti, MA ;
Dougall, WC ;
Smolak, PJ ;
Waugh, JY ;
Smith, CA ;
Goodwin, RG .
IMMUNITY, 1997, 7 (06) :813-820
[9]   AUTOCRINE T-CELL SUICIDE MEDIATED BY APO-1/(FAS/CD95) [J].
DHEIN, J ;
WALCZAK, H ;
BAUMLER, C ;
DEBATIN, KM ;
KRAMMER, PH .
NATURE, 1995, 373 (6513) :438-441
[10]   Long-term protection against the effects of tumor necrosis factor by controlled delivery of the soluble p55 TNF receptor [J].
Eliaz, R ;
Wallach, D ;
Kost, J .
CYTOKINE, 1996, 8 (06) :482-487